Urine IP 10 as a biomarker for assessing the treatment response in pulmonary tuberclosis

Abstract

Background: issue. There are about 10 million TB patients worldwide and among them 4 lakh 84 thousand develop drug resistant tuberculosis. Hence it is necessary to monitor the disease progression and the treatment response early in the course of treatment to find out the probable occurrence of drug resistant infection. Many biomarkers like TNFand#945;, interleukins and others have been estimated to assess the disease severity. However, these are not specific for tuberculosis. Recently the biomarker, interferon gamma relatively specific for tuberculosis, and it can be estimated both in urine and blood. Hence have assessed urinary levels tuberculosis on treatment to determine whether for monitoring newlineObjectives: newlineTo assess the urine the newly diagnosed tuberculosis before, during the treatment. newlineTo correlate the treatment response active pulmonary tuberculosis patients. newlineTo correlate the with sputum examination clinical outcomes newlineMaterials and methods: newline40 the selection the getting, 10ml of urine sample was collected at diagnosis, during the treatment (1st month and 2nd month) and at the end of 6 months. Urine IP-10 was estimated using ELISA kit. Sputum smear and also done diagnosis, 2nd newlineResults: newlineAll 40 participants cooperated with the study procedural requirements and completed the study. The mean urine IP-10 at diagnosis was 10.76±2.76, end of one month 15.37±3.09, end of 2nd month 21.83±4.10 and end of study 8.38±2.46. increased following intensive and decreased significantly towards the end of treatment. Urine IP-10 level was higher with patients who had more than 3 clinical symptoms (mean level 9.8±2.5) at the diagnosis when compared with patients who had less than 3 symptoms (mean level 11.1±2.8). newlineConclusion: newlineThe variation in urinary IP10 level during ATT indicates the response to ATT and bacterial clearance. Hence urinary considered diagnosis and for the response in pulmonary tuberculosis patients. newline